379 related articles for article (PubMed ID: 9607760)
1. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.
Storey A; Thomas M; Kalita A; Harwood C; Gardiol D; Mantovani F; Breuer J; Leigh IM; Matlashewski G; Banks L
Nature; 1998 May; 393(6682):229-34. PubMed ID: 9607760
[TBL] [Abstract][Full Text] [Related]
2. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection.
Minaguchi T; Kanamori Y; Matsushima M; Yoshikawa H; Taketani Y; Nakamura Y
Cancer Res; 1998 Oct; 58(20):4585-6. PubMed ID: 9788606
[TBL] [Abstract][Full Text] [Related]
3. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
4. Papillomavirus and p53.
zur Hausen H
Nature; 1998 May; 393(6682):217. PubMed ID: 9607756
[No Abstract] [Full Text] [Related]
5. The p53 Arg72Pro polymorphism, human papillomavirus, and invasive squamous cell cervical cancer.
Madeleine MM; Shera K; Schwartz SM; Daling JR; Galloway DA; Wipf GC; Carter JJ; McKnight B; McDougall JK
Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):225-7. PubMed ID: 10698487
[TBL] [Abstract][Full Text] [Related]
6. Lack of evidence that proline homozygosity at codon 72 of p53 and rare arginine allele at codon 31 of p21, jointly mediate cervical cancer susceptibility among Indian women.
Bhattacharya P; Sengupta S
Gynecol Oncol; 2005 Oct; 99(1):176-82. PubMed ID: 16054204
[TBL] [Abstract][Full Text] [Related]
7. HPV 16-E6-mediated degradation of intrinsic p53 is compensated by upregulation of p53 gene expression in normal cervical keratinocytes.
Kawamata Y; Mitsuhashi A; Unno Y; Kado S; Shino Y; Uesugi K; Eguchi O; Ishii J; Seki K; Sekiya S; Shirasawa H
Int J Oncol; 2002 Sep; 21(3):561-7. PubMed ID: 12168100
[TBL] [Abstract][Full Text] [Related]
8. [Polymorphism in codon 72 of the p53 gene and cervico-uterine cancer risk in Mexico].
Suárez-Rincón AE; Morán-Moguel MC; Montoya-Fuentes H; Gallegos-Arreola MP; Sánchez-Corona J
Ginecol Obstet Mex; 2002 Jul; 70():344-8. PubMed ID: 12221910
[TBL] [Abstract][Full Text] [Related]
9. p53 polymorphism in human papillomavirus-associated esophageal cancer.
Kawaguchi H; Ohno S; Araki K; Miyazaki M; Saeki H; Watanabe M; Tanaka S; Sugimachi K
Cancer Res; 2000 Jun; 60(11):2753-5. PubMed ID: 10850407
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines.
Mantovani F; Banks L
Oncogene; 1999 Jun; 18(22):3309-15. PubMed ID: 10362351
[TBL] [Abstract][Full Text] [Related]
11. Integration status of virus DNA and p53 codon 72 polymorphism in human papillomavirus type 16 positive cervical cancers.
Szarka K; Veress G; Juhász A; Kónya J; Sápy T; Soós G; Hernádi Z; Gergely L
Anticancer Res; 2000; 20(3B):2161-7. PubMed ID: 10928171
[TBL] [Abstract][Full Text] [Related]
12. The role of TP53 in Cervical carcinogenesis.
Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I
Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117
[TBL] [Abstract][Full Text] [Related]
13. p53 polymorphism and risk of cervical cancer.
Josefsson AM; Magnusson PK; Ylitalo N; Quarforth-Tubbin P; Pontén J; Adami HO; Gyllensten UB
Nature; 1998 Dec; 396(6711):531; author reply 532. PubMed ID: 9859988
[No Abstract] [Full Text] [Related]
14. No relationship observed between human p53 codon-72 genotype and HPV-associated cervical cancer in a population group with a low arginine-72 allele frequency.
Govan VA; Loubser S; Saleh D; Hoffman M; Williamson AL
Int J Immunogenet; 2007 Jun; 34(3):213-7. PubMed ID: 17504512
[TBL] [Abstract][Full Text] [Related]
15. Functional consequences of directed mutations in human papillomavirus E6 proteins: abrogation of p53-mediated cell cycle arrest correlates with p53 binding and degradation in vitro.
Slebos RJ; Kessis TD; Chen AW; Han SM; Hedrick L; Cho KR
Virology; 1995 Apr; 208(1):111-20. PubMed ID: 11831691
[TBL] [Abstract][Full Text] [Related]
16. P53 codon 72Arg polymorphism is not a risk factor for carcinogenesis in the chinese.
Wang NM; Tsai CH; Yeh KT; Chen SJ; Chang JG
Int J Mol Med; 1999 Sep; 4(3):249-52. PubMed ID: 10425273
[TBL] [Abstract][Full Text] [Related]
17. p53 codon 72 polymorphism and HPV status in lung cancer.
Buyru N; Altinisik J; Isin M; Dalay N
Med Sci Monit; 2008 Sep; 14(9):CR493-7. PubMed ID: 18758421
[TBL] [Abstract][Full Text] [Related]
18. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
[TBL] [Abstract][Full Text] [Related]
20. Codon 72 polymorphism of p53 as a risk factor for patients with human papillomavirus-associated squamous intraepithelial lesions and invasive cancer of the uterine cervix.
Yamashita T; Yaginuma Y; Saitoh Y; Kawai K; Kurakane T; Hayashi H; Ishikawa M
Carcinogenesis; 1999 Sep; 20(9):1733-6. PubMed ID: 10469618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
